JDD Special Focus

Atopic Dermatitis Case Reports

Stay up-to-date on new clinical findings in Atopic Dermatitis.  View the latest articles, case reports, supplements, CME activities, Podcast episodes and more!


Case Reports

Dupilumab Treatment for Prurigo Nodularis and Pruritis 

Ross Tanis MD MS, Katalin Ferenczi MD, Michael Payette MD MBAB  J Drugs Dermatol. 2019;18(9):940-942. 

 Prurigo nodularis (PN) is a disease in which chronic scratching and picking of the skin due to intense pruritis results in papulonodules, notably in areas that are accessible to the patient. The pathophysiology is hypothesized to be mediated by a Th2 helper cell response, similar to that seen in atopic dermatitis, therefore, treatment of PN with dupilumab would be expected to elicit a therapeutic response.  


Dupilumab in the Treatment of Dyshidrosis: A Report of Two Cases 

Gillian K. Weston MD, Jette Hooper, Bruce E. Strober MD PhD J Drugs Dermatol. 2018;17(3):355-356. 

We report two cases of recalcitrant dyshidrotic eczema treated successfully with dupilumab at standard dosing. Further studies to establish the efficacy of dupilumab in the treatment of dyshidrosis are warranted. 


Is Dupilumab an Immunosuppressant?

Adrian Cuellar-Barboza MD, Matthew Zirwas MD, Steven R. Feldman MD PhD J Drugs Dermatol. 2020;19(2)209-210 doi:10.36849/JDD.2020.4722
In severe AD, systemic immunosuppressants are often utilized, though they do not target specific biologic pathways of AD. A non-immunosuppressive treatment may offer the possibility of high efficacy with better safety. Dupilumab, the only FDA-approved biologic for AD (approved for adults and adolescents 12 and older), is a fully human monoclonal IgG4ҡ antibody that inhibits IL-4 and IL-13 signal. 


Candida Esophagitis Associated With Mycophenolate Mofetil Treatment of Atopic Dermatitis

Anna Kurayev MD and Alice B. Gottlieb MD PhD J Drugs Dermatol. 2016;15(10):1267-1269.
A case in which a patient developed Candida esophagitis (CE) after treatment of atopic dermatitis (AD) with mycophenolate mofetil (MMF) for 22 months.


Horrendous, Treatment-resistant Pediatric Atopic Dermatitis Solved With a Change in Vehicle

Tejaswi Mudigonda BS, William Kaufman MD, and Steven R. Feldman MD PhD J Drugs Dermatol. 2016;15(1):114-115.
We report a child with horrendous atopic dermatitis whose disease resolved rapidly in the hospital when therapy was changed to a product that was easier to apply.


Podcast Episodes

Choosing Wisely: Capitalizing on Atopic Dermatitis Clinical Trial Data for Meaningful Selection of Topical Agents

We are finally getting what we asked for: Pharma is ponying up for head to head studies to provide us with meaningful data to help make better clinical decisions. However, these valuable projects are often with systemic agents, such as biologics, leaving topical treatments in the dust. To address this, Dr. Lawrence Eichenfield, Professor of Dermatology and Pediatrics, UCSD, and colleagues sought to make the most out of the data we do have on the litany of topical options for atopic dermatitis and provide efficacy and safety guidance (A for effort!). Tune in to hear what this dream team concocted about creams. Hear how an expert approaches new atopic dermatitis patients. Don’t miss out – this is all very topical.

Trending Now: Shifts and Gaps in Atopic Dermatitis Management by Derm and Non-Derm Physicians

Back by popular demand, Dr. Steven Feldman, Professor of Dermatology, Pathology and Public Health joins host Dr. Adam Friedman from GW School of Medicine to review his recent database dive entitled “Trends in Atopic Dermatitis Management: Comparison of 1990-1997 to 2003-2012.” What new trends, both good and bad, have emerged? What can we expect and hope for the future of AD care? What tricks of the trade do these two employ when utilizing systemic immunosuppressants? Itching for answers? Make sure to tune in…

Go superpotent or go home: The utility and safety of Class 1 topical steroids

In this edition of the JDD Podcast, Ask the Investigator, host Dr. Adam Friedman digs deep with UCSF Assistant Professor of Dermatology Dr. Tina Bhutani to powerlift the most up to date safety data on Class 1 superpotent topical steroids from her study entitled “Update on the Systemic Risks of Superpotent Topical Steroids.” Is steroid phobia valid, or does proper use of steroids properly protect from the adverse event boogeyman. Hear from the expert how to effectively use topical steroids while limiting local and systemic side effects, and how to get your patients on board, especially those nay sayers. Do not miss this clinically relevant and im-POTENT podcast ( nailed it!).

We’re Not Alone: The role of the cutaneous microbiota in maintaining skin health

In this special edition of the JDD podcast, with consideration from La Roche-Posay, host Dr. Adam Friedman is joined by Acne guru Dr. Hilary Baldwin, Director of the Acne Research Center and Associate Professor of Dermatology at SUNY Downstate, to review the cutting edge of cutaneous microbiome research and translational applications. Yes you are covered in bacteria – accept it, own it, and love it. Learn how harmony between the >500 species on our skin keep our barrier and cutaneous immunity in check, and conversely, how dysbiosis can facilitate a broad range of cutaneous pathology. This special edition is not to be missed!

CME Library

Choosing Wisely: Capitalizing on Atopic Dermatitis Clinical Trial Data for Meaningful Selection of Topical Agents

Learning Objectives: Upon completion of this enduring activity, participants should be able to discuss the efficacy and safety of different topicals indicated for topic dermatitis, and the unique approaches to managing this complex yet extremely common conditions.


Take CME Now


Translational Lecture Series

Targeting cAMP Signaling for the Treatment of Inflammatory Diseases of the Skin

Dr. Jon Zippin, Assistant Attending Dermatologist and Assistant Professor of Dermatology at Weill Medical College of Cornell, elucidates the complexity of cAMP biology and the translational impact of PDE4 inhibition as it relates to chronic inflammatory skin diseases. Tune in to learn why targeting this pathway is clinically meaningful but also where more work is needed to improve outcomes.

Update on Pediatric Inflammatory Skin Disorders: How Pathogenesis Informs Treatment

Dr. Amy Paller, Walter J. Hamlin Professor and Chair of Dermatology & Professor of Pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, delivers a presentation discussing the cause and treatment of pediatric Atopic Dematitis, including co-morbidities, epidermal barrier impairment, and compliance issues.

Itch form Bedside to Bench

Dr. Gil Yosipovitch, Professor of Dermatology at University of Miami Miller School of Medicine, provides residents and physicians access to the latest bench research and practical pearls from a master in pruritus that will help them offer the highest quality evidence-based dermatological care.


JDD Blog

AcneAestheticsFeatured ArticlesJDD Highlights
February 3, 2021

February issue highlights new perspectives in chronic skin conditions

It’s a hopeful time of year, and the articles published in this month’s issue underscore this hope and transition with researchers bringing forward new perspectives on chronic skin conditions like…
Featured ArticlesJDD Highlights
October 22, 2020

View the Latest Discoveries in Atopic Dermatitis, Anti-Aging, and Medical Dermatology

The October issue of the Journal of Drugs in Dermatology is available now. This month, we focus on atopic dermatitis with special features on Public Health, Anti-aging, Aesthetic, and Medical…
Featured ArticlesJDD Highlights
August 31, 2020

View the Latest Discoveries in Aesthetics, Anti-Aging, and Medical Dermatology

The September issue of the Journal of Drugs in Dermatology is available now. This month, we focus on aesthetic treatments, with special features on Public Health, Anti-aging, Aesthetic, and Medical…
JDD Highlights
August 5, 2020

The Latest Research & Discoveries in Psoriasis, Anti-Aging, Aesthetics, and Medical Dermatology

The August issue of the Journal of Drugs in Dermatology is available now. This month, we focus on Psoriasis, with special features on Public Health, Anti-aging, Aesthetic, and Medical Dermatology.…